Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis 2024: FDA Approvals, Clinical Trials, Therapies, Mechanism of Action, Route of Administration by DelveInsight

Nontuberculous Mycobacterial (NTM) Infections Pipeline

(Las Vegas, Nevada, United States) As per DelveInsight’s assessment, globally, Nontuberculous Mycobacterial (NTM) Infections pipeline constitutes 10+ key companies continuously working towards developing 10+ Nontuberculous Mycobacterial (NTM) Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.

“Nontuberculous Mycobacterial (NTM) Infections Pipeline Insight, 2024″ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Nontuberculous Mycobacterial (NTM) Infections Market.

The Nontuberculous Mycobacterial (NTM) Infections Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.

Request for Sample Report here @ Nontuberculous Mycobacterial (NTM) Infections Pipeline Outlook

Some of the key takeaways from the Nontuberculous Mycobacterial (NTM) Infections Pipeline Report:

• Nontuberculous Mycobacterial (NTM) Infections Companies across the globe are diligently working toward developing novel Nontuberculous Mycobacterial (NTM) Infections treatment therapies with a considerable amount of success over the years. 
• Nontuberculous Mycobacterial (NTM) Infections companies working in the treatment market are Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others, are developing therapies for the Nontuberculous Mycobacterial (NTM) Infections treatment 
• Emerging Nontuberculous Mycobacterial (NTM) Infections therapies such as MNKD-101, Omadacycline, CRS0393, MAT2501, and others are expected to have a significant impact on the Nontuberculous Mycobacterial (NTM) Infections market in the coming years.
• In April 2024, MannKind Corporation announced that the U.S. Food and Drug Administration (FDA) has cleared the company’s Investigational New Drug (IND) application for MNKD-101 (Clofazimine Inhalation Suspension), enabling the initiation of a Phase 3 study for the treatment of nontuberculous mycobacterial (NTM) lung disease.
• In January 2024, Microbion Corporation announced that the company had been granted a second orphan drug designation for its lead drug candidate, pravibismane, for the treatment of non-tuberculous mycobacterial (NTM) infections.
• In September 2023, Insmed had reported positive results from the Phase III ARISE study of ARIKAYCE for the treatment of nontuberculous mycobacterial (NTM) lung disease, caused by Mycobacterium avium complex (MAC). 

Nontuberculous Mycobacterial (NTM) Infections Overview

Nontuberculous Mycobacterial (NTM) infections are caused by a diverse group of mycobacteria that are commonly found in soil, water, and dust. Unlike Mycobacterium tuberculosis, NTM infections are not contagious and typically affect individuals with compromised immune systems or pre-existing lung conditions, such as chronic obstructive pulmonary disease (COPD) or cystic fibrosis. NTM infections can manifest in various forms, including pulmonary disease, lymphadenitis, skin and soft tissue infections, and disseminated disease.

The most prevalent species responsible for NTM pulmonary infections are Mycobacterium avium complex (MAC) and Mycobacterium abscessus. Symptoms of pulmonary NTM infections often resemble those of other respiratory conditions and may include chronic cough, fatigue, weight loss, and night sweats. Diagnosis typically involves a combination of clinical assessment, imaging studies, and microbiological tests, including culture and molecular techniques.

Treatment of NTM infections is challenging due to the intrinsic resistance of mycobacteria to many antibiotics. A typical treatment regimen includes a combination of multiple antibiotics over an extended period, often 12 months or more, based on the specific NTM species and the patient’s response to therapy. Due to the prolonged and complex nature of treatment, patient management often requires a multidisciplinary approach involving pulmonologists, infectious disease specialists, and other healthcare professionals. Despite advances in diagnosis and treatment, NTM infections remain a significant clinical challenge, underscoring the need for ongoing research and development of more effective therapeutic strategies.

Get a Free Sample PDF Report to know more about Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutic Assessment- Nontuberculous Mycobacterial (NTM) Infections Treatment Market

Nontuberculous Mycobacterial (NTM) Infections Route of Administration

Nontuberculous Mycobacterial (NTM) Infections pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as 

• Oral
• Parenteral
• Intravitreal
• Subretinal
• Topical

Nontuberculous Mycobacterial (NTM) Infections Molecule Type

Nontuberculous Mycobacterial (NTM) Infections Products have been categorized under various Molecule types, such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutics Assessment

• Nontuberculous Mycobacterial (NTM) Infections Assessment by Product Type
• Nontuberculous Mycobacterial (NTM) Infections By Stage and Product Type
• Nontuberculous Mycobacterial (NTM) Infections Assessment by Route of Administration
• Nontuberculous Mycobacterial (NTM) Infections By Stage and Route of Administration
• Nontuberculous Mycobacterial (NTM) Infections Assessment by Molecule Type
• Nontuberculous Mycobacterial (NTM) Infections by Stage and Molecule Type

DelveInsight’s Nontuberculous Mycobacterial (NTM) Infections Report covers around 4+ products under different phases of clinical development like-

• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration

Further Nontuberculous Mycobacterial (NTM) Infections product details are provided in the report. Download the Nontuberculous Mycobacterial (NTM) Infections pipeline report to learn more about the emerging Nontuberculous Mycobacterial (NTM) Infections therapies- Nontuberculous Mycobacterial (NTM) Infections Drugs

Nontuberculous Mycobacterial (NTM) Infections Pipeline Analysis:

The Nontuberculous Mycobacterial (NTM) Infections pipeline report provides insights into 

• The Nontuberculous Mycobacterial (NTM) Infections pipeline report provides detailed insights about companies that are developing therapies for the treatment of Nontuberculous Mycobacterial (NTM) Infections with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Nontuberculous Mycobacterial (NTM) Infections Treatment.
• Nontuberculous Mycobacterial (NTM) Infections key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Nontuberculous Mycobacterial (NTM) Infections Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. 
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Nontuberculous Mycobacterial (NTM) Infections market.

Download Sample PDF Report to know more about Nontuberculous Mycobacterial (NTM) Infections drugs and therapies- Nontuberculous Mycobacterial (NTM) Infections Clinical Trials and FDA Approvals

Scope of Nontuberculous Mycobacterial (NTM) Infections Pipeline Drug Insight    

• Coverage: Global
• Key Nontuberculous Mycobacterial (NTM) Infections Companies: Mannkind Corporation, Paratek Pharmaceuticals, Matinas BioPharma, Spero Therapeutics, Crestone, Inc, Vast Therapeutics, and others.
• Key Nontuberculous Mycobacterial (NTM) Infections Therapies: MNKD-101, Omadacycline, CRS0393, MAT2501, and others.
• Nontuberculous Mycobacterial (NTM) Infections Therapeutic Assessment: Nontuberculous Mycobacterial (NTM) Infections current marketed and Nontuberculous Mycobacterial (NTM) Infections emerging therapies
• Nontuberculous Mycobacterial (NTM) Infections Market Dynamics: Nontuberculous Mycobacterial (NTM) Infections market drivers and Nontuberculous Mycobacterial (NTM) Infections market barriers 

Request for Sample PDF Report for Nontuberculous Mycobacterial (NTM) Infections Pipeline Assessment and clinical trials – Nontuberculous Mycobacterial (NTM) Infections Therapeutics Market

Table of Contents

1. Nontuberculous Mycobacterial (NTM) Infections Report Introduction

2. Nontuberculous Mycobacterial (NTM) Infections Executive Summary

3. Nontuberculous Mycobacterial (NTM) Infections Overview     

4. Nontuberculous Mycobacterial (NTM) Infections- Analytical Perspective In-depth Commercial Assessment

5. Nontuberculous Mycobacterial (NTM) Infections Pipeline Therapeutics

6. Nontuberculous Mycobacterial (NTM) Infections Late Stage Products (Phase II/III)

7. Nontuberculous Mycobacterial (NTM) Infections Mid Stage Products (Phase II)

8. Nontuberculous Mycobacterial (NTM) Infections Early Stage Products (Phase I)

9. Nontuberculous Mycobacterial (NTM) Infections Preclinical Stage Products

10. Nontuberculous Mycobacterial (NTM) Infections Therapeutics Assessment

11. Nontuberculous Mycobacterial (NTM) Infections Inactive Products

12. Company-University Collaborations (Licensing/Partnering) Analysis

13. Nontuberculous Mycobacterial (NTM) Infections Companies

14. Nontuberculous Mycobacterial (NTM) Infections Key Products

15. Nontuberculous Mycobacterial (NTM) Infections Unmet Needs

16 . Nontuberculous Mycobacterial (NTM) Infections Market Drivers and Barriers

17. Nontuberculous Mycobacterial (NTM) Infections Future Perspectives and Conclusion

18. Nontuberculous Mycobacterial (NTM) Infections Analyst Views

19. Appendix

20. About DelveInsight

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432, Las Vegas NV 89107
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting